Breathing new life into the treatment of autoimmune pulmonary alveolar proteinosis (aPAP)
About Savara
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.
Learn about Savara
Our Science
Our science is fueled by our desire to provide improved treatment options to people living with rare respiratory diseases.
More about our indication
In Development
Our lead product candidate, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
What's in development
Information for Investors
View our press releases, events, presentations, and other important investor information.
Learn more